Global Federated Genomics Analysis Market Projected to Reach $4.27 Billion by 2030
Yahoo Finance ·
The global federated genomics analysis market is expanding rapidly, moving from $1.64 billion in 2025 to $1.98 billion in 2026 at a 21% compound annual growth rate, according to Research and Markets. The sector is forecast to achieve $4.27 billion by 2030 with a 21.2% CAGR. As tech giants including AWS, Google, Microsoft, and NVIDIA scale privacy-preserving AI, healthcare providers and biotechnology firms increasingly adopt secure architectures to analyze distributed genomic datasets without transferring raw patient information. Strict data privacy mandates, cross-border research initiatives, and the ongoing expansion of precision medicine continue to drive robust investment and technological advancements across international healthcare ecosystems.
AI 시장 분석
The global federated genomic analysis market is projected to reach $4.27 billion by 2030, growing at a CAGR of 21.2%. Big tech companies such as AWS, Google, Microsoft, and NVIDIA are accelerating market growth by expanding privacy-preserving AI and cloud infrastructure. Investors should look for new growth opportunities in precision medicine and security-focused healthcare technology sectors.
상승 영향
- AI — AWS, Google, Microsoft, and NVIDIA are expanding privacy-preserving AI platforms, directly benefiting from the market growing to $4.27 billion by 2030.
- Biotechnology — The federated genomic analysis market is recording a CAGR of 21.2%, rapidly increasing the demand for secure data analysis for precision medicine research and personalized therapeutics development.
DYAX 전담 분석
The federated genomic analysis market is expected to surge from $1.64 billion in 2025 to $4.27 billion in 2030, recording a high CAGR of 21.2%. This is directly driven by tightened medical data security regulations and a surge in demand for privacy-preserving AI.
The bullish scenario involves a rapid increase in software and infrastructure revenue driven by accelerated cloud and AI integration by big tech companies, while the bearish scenario points to data security regulatory risks or collaboration delays. Key monitoring metrics are the number of precision medicine approvals and the adoption rate of cloud security solutions.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 39% · Bearish (Short) 61%
395 participants
Related News
- Alphabet Loses $482B in Market Value as AI Spending Surges
- Analysis Behind the Sharp Decline in Medical Prop Tr Shares
- B Riley Highlights Key AdTech Stocks to Watch Ahead of Q3 Earnings
- Mobile Virtualization Market Report 2026: Valuation Projected to Hit US$21 Billion by 2032
- Teva Stock Doubles in a Year: What to Expect Over the Next Three Years
- Reasons Behind Sandisk's Recent Stock Plunge
